EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Resurgence and Predominance of GII.17[P17] Norovirus in Children With Sporadic Acute Gastroenteritis in Shanghai, China

Li‐juan Lu, Hua‐qing Zhong, Ran Jia, Meng‐hua Xu, Peng‐cheng Liu, Xun‐hua Zhu, Jin Xu

Journal of Medical Virology · 2025-12 · 97 (12)

DOI: 10.1002/jmv.70729 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Human norovirus has been identified as a significant causative agent of acute gastroenteritis on a global scale. We investigated the epidemiological of norovirus infections in children with acute gastroenteritis in Shanghai between January 2022 and December 2024. The overall prevalence of norovirus was 13.22% (281/2126), with annual rates of 3.77% (20/531) in 2022, 18.30% (149/814) in 2023, and 14.34% (112/781) in 2024. The 281 norovirus strains were classified into the GI group (0.71%, 2/281) and GII group (99.29%, 279/281). Phylogenetic analysis revealed that 90.39% (254/281) of HuNoV strains were successfully genotyped for both VP1 and RdRp genes, with 15 distinct genotype combinations. The most prevalent strain was GII.4 Sydney[P16] (52.36%, 133/254), followed by GII.17[P17] (21.26%, 54/254) and GII.3[P12] (11.42%, 29/254). Of note, GII.4 Sydney[P16] was observed in both 2022 (56.25%, 9/16) and 2023 (74.10%, 103/139), while GII.17[P17] emerged as the predominant genotype in 2024 (43.43%, 43/99). Furthermore, most of the GII.17[P17] strains identified in 2024 clustered with GII.17[P17] strains identified in the United States in 2025. These findings provide new insights into the genetic diversity of HuNoV and indicate a resurgence of a new GII.17[P17], which has become a leading cause of sporadic AGE in children in Shanghai.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →